This Week’s Biotech Highlights
About 82% of Canadians were already happy with Obama in February, but this week I suspect he converted a few of the holdouts with his call for restoring scientific integrity to government decision making. All was subsequently peaceful and happy in the U.S. of A., leading to M&A rapprochement between Roche and Genentech and to Gilead Sciences riding to CV Therapeutics’ rescue.
M&A developments were not so peaceful and happy in Canada, where the Special Committee formed by Patheon’s Board called a takeover bid by JLL Partners “substantially undervalued, opportunistic and structurally coercive.” Merck and Schering-Plough did . . . [more]